76
|
Heredia V, Mendiola M, Ortiz E, Bernabéu D, Pozo-Kreilinger J, Miguel M, Crespo R, Berjón A, Martínez-Marín V, Redondo A. AG-120, a novel IDH1 targeted molecule, inhibits invasion and migration of chondrosarcoma cells in vitro. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.049] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
77
|
Mendiola M, Heredia-Soto V, Herranz J, Martín R, Zamora Auñón P, Castelo B, Pinto Marin A, Miguel M, Crespo R, Ramírez de Molina A, Hardisson D, Espinosa E, Redondo A. Micro-RNA profile in advanced metastatic breast cancer as a predictive tool for response to bevacizumab-paclitaxel. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
78
|
García-Donas J, Garrigos L, Lainez N, Santaballa A, Redondo A, Cueva JF, Rubio MJ, Prieto M, Lopez-Guerrero JA, Garcia-Casado Z, Grande E, Guerra Alia E, Bover I, Hernando Polo S, Sanchez-escribano R, Hurtado A, Navarro P, Rodriguez-Moreno JF. Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.5577] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5577 Background: Granulosa-cell tumors (GCT) of the ovary are a rare entity characterized by presenting a punctual mutation at the FOXL2 gene 402C→G (C134W). Such mutation leads to a disregulation and overstimulation of the steroidogenic pathway and, ultimately, hormone overproduction. A prior trial by our group (GREKO I trial-GETHI 2011-03; NCT01584297) showed promising activity of ketoconazole, a CYP17 inhibitor used to control steroidogenesis in several conditions. Thus, we aimed to assess the activity of Orteronel (TAK700), a selective inhibitor of 17, 20-lyase, in GCT. Methods: An open-label phase II single arm clinical trial was designed for women with metastatic or locally advanced non-resectable GCT who harbored the somatic mutation FOXL2 402C→G (C134W) and who had not received prior treatment with any CYP17 inhibitor. Treatment consisted on Orteronel 300mg BID, given orally, continuously in a 28-day treatment cycle. The primary objective was clinical benefit rate; secondary objectives were response rate, progression free and overall survival, assessment of the impact of Orteronel in reducing hormonal overproduction and toxicity. Sample size calculation was based on a two stage Simon´s design. A power of 80% was set to differentiate between a 5% and a 25% clinical benefit rate. 20% of losses had been assumed thus 20 patients were scheduled to be enrolled. Results: Since 30/06/2014 to 11/01/2017 10 patients have been included in 9 participating institutions members of Spanish Group for Research in Orphan and Unfrequent Tumors (GETHI). Due to a low recrutiment rate the study was terminated early. Median PFS was 3 months 95%CI (0-12) with 3 patients achieving disease stabilization longer than 12 months. 2 patients remain on treatment after 16 and 14 months. Clinical benefit rate (CR + PR + SD) was 50%, 95%CI (19%-81%). Seven patients have progressed and 2 have died. Only 6 suspected unresected adverse reactions (SUSARs) have been communicated so far (chest pain, fever, febrile neutropenia, eosinophila, neutropenia and anemia). Conclusions: Orteronel achieved a significant clinical benefit in advanced GCT with an favorable toxicity profile. Clinical trial information: NCT02101684.
Collapse
|
79
|
Gallego A, Martinez B, Espinosa E, Ghanem I, Ruiz-Gimenez L, Garcia T, Gonzalez T, Castelo B, Zamora P, Redondo A, Feliu J. Long-term cancer survivors: Satisfaction with medical care and information received during the diagnosis and treatment of cancer. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e21573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21573 Background: Long-term survival rates for many types of cancer have substantially improved in past decades. A specific medical office was started up two years ago at our institution for the follow-up and comprehensive care of this population. Long-term cancer survivors were surveyed to know how they perceive medical care and information received during the diagnosis and treatment of cancer. Methods: A 54-item questionnaire was developed based on QLACS (Quality of Life in Adult Cancer Survivors). 286 patients completed the questionnaire from January 2015 to December 2016. All of them were disease-free and without any antitumour therapy for at least two years. The information was collected in a database and processed with SPSS 18. Results: Median age at the time of diagnosis was 56 years. Colorectal and breast carcinomas accounted for 54% of all cases and 61% of patients had been diagnosed in early stages of disease. Median time from cancer diagnosis to questionnaire completion was 104 months (range 29-444 months). Sixty-seven per cent of patients were satisfied with the information received by their oncologist about their cancer, although information provided about other health issues was less satisfactory. Twenty-eight per cent reported that the oncologist never made recommendations about healthy lifestyle. In fact, only 8 patients (2.8%) made dietary modifications, all regular alcohol drinkers (31.1%) maintained their daily intake and 73 patients (25.5%) gained 5 kg over their recommended weight. Anxiety/depression symptoms were reported by 30% of the best informed patients about cancer treatment and 52% of the worst informed. Only 12.4% of long-term cancer survivors of our study consulted their family doctor during the last year, while 75.4% visited their oncologist. Finally, the medical care of the oncologist was satisfactory for 235 patients (83.2%), receiving an overall score of 8.7 on a 0 to 10 scale. Conclusions: Most long-term cancer survivors feel satisfied with the medical care received, but the information provided about other health aspects should be improved. Furthermore, although they rely on their family doctors, most prefer being followed-up by their oncologist.
Collapse
|
80
|
Stacchiotti S, Ferrari S, Redondo A, Palmerini E, Hindi N, Vaz MA, Frezza AM, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Ranchère-Vince D, Collini P, Cruz J, Martin Broto J. International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.11062] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11062 Background: Extraskeletal myxoid chondrosarcoma (EMC) is an exceedingly rare sarcoma, marked by a specific translocation involving the gene NR4A3 that can be rearranged with different partners. Preliminary retrospective data suggest that sunitinib is active, but no formal prospective studies are available. We report on a multicentric European prospective, investigator-driven, Phase 2 study on pazopanib (P) in NR4A3+ advanced EMC patients (pts), carried out by the Spanish, Italian and French Sarcoma groups. Methods: From June 2014 to November 2016, 24 advanced EMC pts entered this study (median age: 64 yrs - disease extent: metastatic 77%, locally advanced 23% - prior medical treatment: 18 (86%) naive; 2 (9%) 1 line, 1 (5%) > 1 line). Path diagnosis and NR4A3 rearrangement (FISH and/or real-time PCR analysis) were centrally confirmed. Pts received P 800 mg/day (relative dose intensity = 0,82%, 658 mg/day), until progression or toxicity. The primary study end-point was response rate as per RECIST 1.1. Secondary end-points were overall survival, progression-free survival (PFS), clinical benefit rate (CBR) (RECIST CR+PR+SD≥6mos). An exploratory evaluation of the correlation between the rearrangement subtype and the outcome is ongoing. Results: 20/24 pts were evaluable for response (1 early death; 3 too early). One patient (5%) had a partial response, 17 (75%) stable disease, 2 (10%) progression as their best RECIST responses. At the time of this analysis, 12 pts were still under treatment, while 12 interrupted P (10 progression, 1 toxicity, 1 other). At a 13-month median follow-up, the median PFS was 13 months (range 1.6-25.1), with 29% pts progression-free at 18 months and a 65% CBR. Median OS was not reached. Conclusions: This Phase 2 study is formally negative since the target of at least 3/21 RECIST responses was not reached. However, looking at PFS, P was associated with a prolonged disease stabilization in a significant proportion of pts. This suggests to further explore the use of P in EMC. Clinical trial information: NCT02066285.
Collapse
|
81
|
Ramos Vazquez M, Redondo A, Manso L, Gil M, Garau I, Perez-Carrion R, Garcia-Garre E, Rodriguez CA, Chacon JI, Lopez-Vivanco G. Long-term responders to first-line bevacizumab-based therapy in metastatic breast cancer (MBC) patients: Results of the observational study LORENA. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e12563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12563 Background: Randomized controlled trials in MBC patients evaluating bevacizumab as first-line treatment showed improvements in tumor response and progression-free survival (PFS) when added to chemotherapy. The aim of the LORENA study was to describe the clinical features, prognosis factors and safety of bevacizumab and chemotherapy treatment for MBC in routine practice. Methods: Observational, multicentre, ambispective study conducted in Spain. The study had a retrospective and a prospective phase. Data were obtained from March 2012 to October 2013. In the retrospective phase, eligible patients were women with metastatic or locally-advanced breast cancer, treated with bevacizumab as a first-line therapy, and progression-free survival for ≥ 12 months. In the prospective phase, patients were followed-up and assessed as per routine clinical practice. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Univariate and multivariate analyses of prognostic factors were performed. Results: 148 women from 38 centers were included. The mean age was 52 (±11) years. Bone, lung and liver were the most frequent metastasis sites. 138 patients were HER2-neg. on diagnosis (data unknown in 10 patients). The mean exposure to bevacizumab was 18 (±11) months. Most patients had objective response, 23% complete response, and 57% partial response. Median OS was 58.2 months and median PFS was 22.7 months. In multivariate analyses, OS was higher in patients with hormonal maintenance therapy (HMT) (p = 0.009; HR = 2.0) and in patients not treated with taxanes before the metastatic diagnosis (p < 0.0001; HR = 3.3); also, PFS was higher in patients with HMT (p = 0.002; HR = 1.8). No adverse events were observed other than those reported previously. Conclusions: Outcomes of OS and PFS suggest a benefit from bevacizumab maintained therapy. HMT was a PFS prognosis factor. HMT and not having been treated with taxanes before the metastatic diagnosis were two independent OS prognosis factors. Our results could provide further evidence supporting the use of bevacizumab as maintenance therapy for MBC patients.
Collapse
|
82
|
Matulonis UA, Herrstedt J, Tinker A, Marme F, Redondo A, Kalbacher E, Ledermann JA, Pikiel J, Christensen RD, Berek JS, Juhler-Nøttrup T, Oza AM, Meier W, Gil-Martin M, Hardy-Bessard AC, Monk BJ, Rosenberg P, Wenham RM, Hazard S, Mirza MR. Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.5534] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5534 Background: Current therapies for recurrent OC include chemotherapy (C) or bevacizumab (B) in combination with C followed by continuous B, which showed improved progression-free survival (PFS) compared with C followed by placebo (P) over 3.4 months (GOG-0213) or 4.0 months (OCEANS). Potential impact of B on effectiveness of subsequent therapies has not been described. Niraparib (N) is a highly selective PARP 1/2 inhibitor (PARPi). In preclinical studies, N concentrates in the tumor; N showed significantly longer PFS vs P in patients (pts) with recurrent OC following complete/partial response (CR/PR) to platinum based chemotherapy (Plat) in the randomized, controlled, double-blind phase 3 ENGOT-OV16/NOVA trial. We report the long term effect of treatment with N and its impact on subsequent therapy. Methods: Eligibility for NOVA included recurrent OC, fallopian tube or peritoneal cancer, no prior PARPi use, and completion of ≥2 prior courses of Plat, with a CR or PR following the most recent Plat. Pts were enrolled into g BRCAmut or non-g BRCAmut cohorts based on BRCA mutation test results and randomized 2:1 to receive N 300 mg qd or P until progression of disease or death (PD). Tumors were tested for homologous recombination deficiency (HRD). Estimated probability of PD in each cohort at 12, 18 and 24 months post randomization, representing ~18, 24 and 30 months post chemotherapy initiation, was determined; the difference between PFS2 and PFS (PFS2-PFS) was evaluated in all randomized pts. Results: 203 pts were randomized in the g BRCAmut cohort. Of 350 pts randomized in the non-g BRCAmut cohort, 162 had HRD+ and 134 HRD− tumors. Estimated probability (product-limit method) of PFS at 12, 18 and 24 months was greater in the niraparib arm than in the placebo arm in each cohort and subgroup at each time interval. Probabilities (95% CI) at 24 months for niraparib vs control were 0.42 (0.30, 0.55) vs 0.16 (0.07, 0.28) (gBRCAmut) and 0.27 (0.19, 0.35) vs 0.12 (0.06, 0.21) (non-gBRCAmut). PFS2-PFS was similar in the 2 treatment arms in the combined cohorts (HR 1.02, 95% CI 0.765, 1.349). Conclusions: Niraparib provided long term benefit in pts with recurrent OC irrespective of g BRCAmut or HRD status, and no decrement in the benefit of subsequent therapy was observed. Clinical trial information: NCT01847274.
Collapse
|
83
|
Romero I, Leskella S, Redondo A, Gutierrez-Pecharroman A, Santaballa A, Cristobal Lana EM, Calvo E, Rosa-Rosa JM, Oaknin A, Bover I, Herrero A, Sanchez-Heras AB, Churruca CM, De Juan A, Mendiola C, Romeo M, Ojeda B, Lopez-Guerrero JA, Palacios J, Poveda A. CD8 + TILs in early stage epithelial ovarian cancer: A GEICO study. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.5543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5543 Background: The extent of tumor infiltrating lymphocytes (TILs) has emerged as a potential clinical useful biomarker in epithelial ovarian cancer (OC); however differences in TILs among OC histological types have not been extensively analysed. Methods: From a prospective early stage (I-II) GEICO registry of 1151 cases, 573 were sent for central pathology review. Complete analysis for classification of OC correctly identified 488 cases. Histological typing was performed according to morphological features and the expression of WT1, p53, p16, estrogen receptor (ER), progesterone receptor, and napsin A. The expression of mismatch repair (MMR) proteins MLH1, PMS2, MSH2 and MSH6 was performed in all tumors. The absolute number of stromal and intraepithelial CD8+ TILs per 0.6 mm2 TMA core was quantified and correlated with pathological features. Results: The series included 127 high-grade serous carcinomas (HGSC) (26%), 22 low-grade serous carcinomas (LGSOC) (4.5%), 165 endometrioid carcinomas (EC) (33.8%), 124 clear cell carcinomas (CCC) (2.4%), and 50 mucinous carcinomas (MC) (10.2%). The mean of intraepithelial CD8+ TILs was higher in HGSG (48.7) than in all other histological types (LGSG: 16.3; EC: 27.1; MC: 7.0; and CCC 10.3; p<0.0001). In the stromal component, the mean of CD8+TILs was also higher in HGSG (31.1) than in EC, MC and CCC (15.8, 8.0 and 12.7, respectively; p<0.0001). The mean of intraepithelial CD8+ TILs was significantly higher in RE-positive (71.9) than in RE-negative (34.8) HGSC ( p=0.002). In the complete series, 33 (6.6%) OCs showed absent expression of at least 1 MMR protein, and the mean of intraepithelial CD8+ TILs was significantly higher in these OCs (57.0) than in those with preserved expression of all MMR proteins (23.6; p=0.0035). MMR protein deficiency was observed in 27 (16%) ECs, and these tumours had significantly higher mean of both intraepithelial (60.4 vs. 20.7 p=0.003) and stromal CD8+ TILs (26.6 vs. 13.8, p= 0.046). No significant differences in TILs were observed among EC of different histological grades. Conclusions: The extent of CD8+TILs significantly correlates with the histological type and MMR status in OCs, being HGSCs and EC with MMR deficiency those OCs with higher CD8+TILs.
Collapse
|
84
|
Martin Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, Casali PG, Italiano A, Grignani G, Dumont S, Garcia del Muro X, Gutierrez A, Martinez Trufero J, Palmerini E, Hindi N, de Alava E, Collini P, Ranchère-Vince D, Blay JY, Cruz J. Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.11003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11003 Background: SFT is a rare soft tissue tumor. In advanced SFT chemotherapy has only limited activity. With the rationale of a rich vascular network & VEGF (tumor cells and endothelium) and VEGFR1/2 (endothelial cells) expression in SFT, we designed an international, single-arm phase II trial to test pazopanib (P) in advanced SFT. Clinical and preclinical evidence suggesting that antiangiogenics was less effective in more aggressive compared with less aggressive SFT (Stacchiotti et al), led us to conduct the trial on two different cohorts: typical and malignant (M)/dedifferentiated (DD) SFT. Here we present the outcome of the latter cohort. Methods: Most relevant inclusion criteria were: unresectable or metastatic, M/DD SFT confirmed by central pathologic review with evidence of STAT6 (IHC and /or FISH or RT-PCR), ≥ 18 years, ECOG 0-2, progressive and measurable disease. Main endpoint was response rate (RR) according Choi criteria. Central radiological assessment was mandatory. P was administered at 800 mg/d continuously until progression or toxicity. Results: From June 2014 to November 2016, 34 patients (pts) were enrolled with a median age of 61 y (23-87). Median tumor size and mitosis at diagnosis were 77 mm and 8x10 HPF. Most relevant grade 3-4 toxicity were neutropenia (9%) and hypertension (12%). At the time of the present analysis, 31 pts are evaluable for response. RR according to Choi and RECIST were: PR 16 (52%), SD 7 (22%), PD 8 (26%) and PR 1 (3%), SD 19 (61%), PD 11 (35%) respectively. With a median follow-up of 15 months, the median PFS was 5.53 months (4.24-6.82), while 72% survived at 18 months. Size > 5 cm, mitosis > 8 and DD subtype showed significantly worse PFS. The 18-month OS was 90% for those with SD and PR and 25% for PD according to Choi (p < 0.001), while 94% for SD and PR and 45% for PD according RECIST (p = 0.002). In multivariate analysis, only Choi was an independent prognostic factor for OS with PD showing a HR of 11.9 (2.3-63.1), p = 0.003 for the risk of death. Conclusions: Pazopanib showed activity in malignant SFT. Choi criteria exhibited a more accurate assessment of response than RECIST. Clinical trial information: NCT02066285.
Collapse
|
85
|
Karam A, Ledermann J, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger R, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers R, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol 2017; 28:711-717. [DOI: 10.1093/annonc/mdx011] [Citation(s) in RCA: 95] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Indexed: 11/13/2022] Open
|
86
|
Martínez-Marín V, Redondo A, Heredia V, Guerra L, Miguel-Martín M, Crespo R, Hardisson D, Feliu J, Mendiola M. Comparison of two-dimensional (2D)- and three-dimensional (3D)-culture models as drug testing platforms in GIST: experience with axitinib in vitro. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30580-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
87
|
Santaballa A, Barretina P, Casado A, García Y, González-Martín A, Guerra E, Laínez N, Martinez J, Redondo A, Romero I. SEOM Clinical Guideline in ovarian cancer (2016). Clin Transl Oncol 2016; 18:1206-1212. [PMID: 27905052 PMCID: PMC5138249 DOI: 10.1007/s12094-016-1588-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Accepted: 11/17/2016] [Indexed: 12/01/2022]
Abstract
Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer (OC) is the first cause of death due to gynecological cancer and the fifth cause of death for cancer in women in Spain. The aim of this guideline is to summarize the current evidence and to give evidence-based recommendations for clinical practice.
Collapse
|
88
|
Mirza M, Monk B, Oza A, Mahner S, Redondo A, Fabbro M, Ledermann J, Lorusso D, Vergote I, Rosengarten O, Berek J, Herrstedt J, Tinker A, Dubois A, Martin AG, Follana P, Benigno B, Rimel B, Agarwal S, Matulonis U. gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.26] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
89
|
Redondo A, Morales CV, Hindi N, Lopez-Martin J, Honigschmidt G, Zeng Y, Chen J, Tai D, Mo G, Ilaria R, Pillay N, Drove N, Jamarik M. ANNOUNCE 2: An open-label phase 1b, and a randomized, double-blind phase 2 study of olaratumab with gemcitabine plus docetaxel in the treatment of patients with advanced soft tissue sarcoma (STS). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw388.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
90
|
Martin Broto J, Fernandez-Serra A, Lopez-Pousa A, Gutierrez A, De Las Penas R, Martinez-Trufero J, Cruz J, Alvarez RM, Cubedo R, Redondo A, Carrasco JA, Lopez-Martin JA, Sala MÁ, Sevilla I, Balana C, Vaz Salgado MÁ, De Juan A, Poveda A, Hindi N, Lopez-Guerrero JA. CUL4A and ERCC1 genesas predictive factors for trabectedin efficacy in advanced soft tissue sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.11048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
91
|
Garrigos L, Santaballa A, Hurtado A, Rodriguez-Moreno JF, Sanchez-escribano R, Redondo A, Lainez N, Rubio MJ, Bover I, Cueva JF, Hernando Polo S, Izquierdo Manuel M, Prieto M, Lopez-Guerrero JA, Garcia-Casado Z, Perez I, De Las Penas R, Grande E, García-Donas J. Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.tps2598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
92
|
Gaillard S, Ghamande SA, Pardo B, Lorusso D, Vergote I, Papai Z, O'Malley D, Kristeleit RS, Redondo A, Timcheva C, Fernandez C, Nieto A, Soto-Matos A, Moss KR, Baumann KH, Ray-Coquard I, Oaknin A. CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.tps5597] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
93
|
Oaknin A, Rubio MJ, Redondo A, De Juan A, Cueva Bañuelos JF, Gil-Martin M, Ortega E, Garcia-Arias A, Gonzalez-Martin A, Bover I. SEOM guidelines for cervical cancer. Clin Transl Oncol 2015; 17:1036-42. [PMID: 26650487 PMCID: PMC4689764 DOI: 10.1007/s12094-015-1452-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Accepted: 11/08/2015] [Indexed: 12/01/2022]
Abstract
Cervical cancer (CC) is the second most common cancer worldwide, strongly linked to high-risk human papilloma virus infection. Although screening programs have led to a relevant reduction in the incidence and mortality due to CC in developed countries, it is still an important cause of mortality in undeveloped countries. Clinical stage is still the most relevant prognostic factor. In early stages, the primary treatment is surgery or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. In the setting of recurrent or metastatic CC, for the first time ever, the combination of chemotherapy plus bevacizumab prolongs the overall survival beyond 12 months. Therefore, this regimen is considered by most of the oncologist a new standard of care for metastatic/recurrent CC.
Collapse
|
94
|
Heredia V, Redondo A, Barriuso J, Berjón A, Perna C, Cruz P, Hernández A, de Santiago J, Díaz E, Miguel M, Castelo B, Yébenes L, Feliú J, Hardisson D, Mendiola M. Abstract 4838: Inhibitor of differentiation-1 (Id1) expression correlates with epithelial-mesenchymal transition (EMT)-related proteins in epithelial ovarian cancer (EOC) and constitutes a novel prognostic factor. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-4838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aim
The first aim of this work was to investigate the expression of inhibitors of differentiation (ID) proteins in advanced Epithelial Ovarian Cancer (EOC) and its relation with Epithelial to Mesenchymal (EMT)-related markers. Secondly, we also studied their relation with patient clinical and pathological characteristics in order to establish their role as prognostic factors.
Methods
ID proteins expression was analyzed in 59 samples from EOC patients. We performed inmunohistochemistry (IHC) on tissue microarray sections with specific antibodies for ID1, ID2, ID3 and ID4. Immunoreactivity was H-scored for intensity (range 0 to 3) multiplied by percentage of positive cells. It has been previously described that ID genes are involved in EMT, so we correlated IDs with EMT- regulators, including ECAD, ZEB1, ZEB2, SNAIL, SLUG, LOX and LOXL2. We also explored their relation with clinical variables in our cohort.
Results
ID2 and ID3 proteins are uniformly expressed in our EOC series. ID1 and ID2 are also overexpressed in different proportions (41% and 88% of cases respectively). No correlation between increased ID proteins expression and histological subtype, tumor grading, debulking surgery status or treatment response was detected. We have found that ID1 overexpression correlates with prognosis, for Overall Survival (OS), HR: 1.05 (95% CI: 1.02 - 1.07) in the univariate analysis and for Time to Treatment Failure (TTF) in both, uni- and multivariate analysis adjusted to clinical factors (HR: 1.06; 95%CI: 1.02 - 1.1). This finding was confirmed when specifically analyzing the worst prognosis group of patients with high grade serous malignancies. ID1 is known to be associated with more invasive features of cancer and with the EMT. In our cohort, its expression is correlated with some EMT-regulators, as ECAD and SLUG (p < 0,005).
Conclusions
ID proteins expression is frequently deregulated in EOC patients and it seems to influence clinical prognosis, mainly, ID1. Their usefulness as prognostic biomarkers should be further investigated in larger series.
Citation Format: Victoria Heredia, Andres Redondo, Jorge Barriuso, Alberto Berjón, Cristian Perna, Patricia Cruz, Alicia Hernández, Javier de Santiago, Esther Díaz, María Miguel, Beatriz Castelo, Laura Yébenes, Jaime Feliú, David Hardisson, Marta Mendiola. Inhibitor of differentiation-1 (Id1) expression correlates with epithelial-mesenchymal transition (EMT)-related proteins in epithelial ovarian cancer (EOC) and constitutes a novel prognostic factor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4838. doi:10.1158/1538-7445.AM2015-4838
Collapse
|
95
|
Pinto A, Zamora P, Redondo A, Castelo B, Martinez B, Espinosa E. Neutrophil-lymphocite ratio in stage II-III testicular germ cell tumors before initiating chemotherapy: Correlation with survival. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e15564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
96
|
Pose A, guez E, ndez A, mez J, Redondo A, guez E, Ramos E, rrez A, Molt M, Roche D, Ugalde Y, pez A. Dual function of the hemagglutinin H5 fused to chicken CD154 in a potential strategy of DIVA against avian influenza disease: preliminary study. Open Vet J 2015. [DOI: 10.5455/ovj.2015.v5.i2.p138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
In this study we demonstrated that the vaccine candidate against avian influenza virus H5N1 based on the hemagglutinin H5 (HA) fused to the chicken CD154 (HACD) can also be used for differentiating infected from vaccinated animals (DIVA). As the strategy of DIVA requires at least two proteins, we obtained a variant of the nucleoprotein (NP49-375) in E. coli. After its purification by IMAC, the competence of the proteins NP49-375 and HACD as coating antigens in indirect ELISA assays were tested by using the sera of chickens immunized with the proteins HA and HACD and the reference sera from several avian influenza subtypes. Together with these sera, the sera from different species of birds and the sera of chickens infected with other avian viral diseases were analyzed by competition ELISA assays coated with the proteins NP49-375 and HACD. The results showed that the segment CD154 in the chimeric protein HACD did not interfere with the recognition of the molecule HA by its specific antibodies. Also, we observed variable detection levels when the reference sera were analyzed in the ELISA plates coated with the protein NP49-375. Moreover, only the antibodies of the reference serum subtype H5 were detected in the ELISA plates coated with the protein HACD. The competition ELISA assays showed percentages of inhibition of 88-91% for the positives sera and less than 20% for the negative sera. We fixed the cut-off value of these assays at 25%. No antibody detection was observed in the sera from different species of birds or the sera of chickens infected with other avian viral diseases. This study supported the fact that the ELISA assays using the proteins NP49-375 and HACD could be valuable tools for avian influenza surveillance and as a strategy of DIVA for counteracting the highly pathogenic avian influenza virus H5N1 outbreaks.
Collapse
|
97
|
Gonzalez-Martín A, Bover I, Del Campo JM, Redondo A, Vidal L. SEOM guideline in ovarian cancer 2014. Clin Transl Oncol 2014; 16:1067-71. [PMID: 25351169 PMCID: PMC4239783 DOI: 10.1007/s12094-014-1229-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Accepted: 09/12/2014] [Indexed: 11/24/2022]
Abstract
Ovarian cancer is the leading cause of death due to gynecological cancer and the 5th cause of death for cancer in women in Europe. Optimal management of patients with ovarian cancer needs the participation of a well-trained multidisciplinary team. In the last few years, we have observed a significant improvement in the knowledge of the molecular biology of the different histotypes of ovarian cancer that will probably change our standard of care in the forthcoming years. In this Guideline, we summarize the most current evidence for the medical management of ovarian cancer.
Collapse
|
98
|
Maurel J, Lopez-Pousa A, Calabuig S, Bagué S, Del Muro XG, Sanjuan X, Rubió J, Cuatrecasas M, Martinez-Trufero J, Horndler C, Fra J, Morales CV, Redondo A, Poveda A, Sevilla I, Lainez N, Rubini M, Albéniz XG, Broto JM, De Álava E. Prognosis of Phosphorylated-Insulin Growth Factor Receptor (P-Igf-1R) and Metalloproteinase-3 (Mmp3) Expression in Advanced Gastrointestinal Stromal Tumors (Gist) Patients Treated with Imatinib. a Geis Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.61] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
99
|
Mendiola M, Redondo A, Barriuso J, Heredia V, Cruz P, Castelo Fernández B, De Santiago J, Diaz E, Miguel M, Yebenes L, Hardisson D. Association Between Angiogenesis-Related Genes and the Response to Multimodal Therapy in High Grade Serous Advanced Ovarian Carcinoma (Aoc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu338.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
100
|
Iglesias L, Castelo Fernández B, Álvarez R, Ballesteros A, Ghanem I, Nuñez Sobrino J, San Juan Del Moral A, Rogado J, Diaz A, Redondo A, Garcia-Adrian S. Head and Neck Cancer in the Elderly: is There Any Reason to Change Their Management? Ann Oncol 2014. [DOI: 10.1093/annonc/mdu340.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|